Caroline Wigerup

Caroline Wigerup, PhD, is Vice President, Research and Business Operations at Acrivon Therapeutics and Deputy Site Head of Acrivon AB, the company’s wholly owned Swedish subsidiary located at Medicon Village in Lund, Sweden.

Since joining Acrivon in its early stages, Caroline has played a key role in building and advancing the company’s research operations in Sweden. Over more than eight years at Acrivon, she has led cross-functional research activities spanning early drug discovery, translational research, biomarker development, and the advancement of therapeutic programs toward clinical development. Her work has contributed to the translation of Acrivon’s proprietary AP3 precision medicine platform into multiple drug discovery and precision medicine programs, including the development of predictive biomarkers and advancement of novel oncology therapeutics. In her current role, she combines scientific leadership with responsibility for business and site operations at Acrivon AB.

Prior to joining Acrivon, Caroline was a Principal Investigator at Lund University, where her research focused on pediatric cancer biology. She completed her PhD and postdoctoral training at Lund University, with a focus on oncology, cell signaling, and molecular mechanisms underlying therapeutic response.